Company: MDXG
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001376339-25-000009
Chunk: 8

Company: MIMEDX GROUP, INC.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 8
---
,840 — — — 87,870 Net income— — — — — 58,228 58,228 Balance at December 31, 2023146,227,639 $146 $276,249 — $— $(133,678)$142,717 Share-based compensation expense— — 16,933 — — — 16,933 Employee stock purchase plan245,640 — 1,582 — — — 1,582 Issuance of restricted stock, net1,451,067 2 (2,643)— — — (2,641)Exercise of stock options207,686 — 1,397 — — — 1,397 Shares received in settlement of litigation(1,200,000)(1)(9,299)— — — (9,300)Net income— — — — — 42,419 42,419 Balance at December 31, 2024146,932,032 $147 $284,219 — $— $(91,259)$193,107 

See notes to the consolidated financial statements.

F- 8

MIMEDX GROUP, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1.Nature of Business

MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, “MIMEDX,” or the “Company”) is a pioneer and leader in placental biologics focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. All of our products sold in the United States are regulated by the United States Food and Drug Administration (“FDA”).The Company’s product portfolio and product development focuses on Wound and Surgical markets.The Company’s business is focused primarily on the United States of America but the Company also has a small commercial presence in several international locations, including Japan.

2.    Significant Accounting Policies

Principles of ConsolidationThe consolidated financial statements include the accounts